(Solid Tumors) Is Zanidatamab Effective?
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- November 25, 2022
- 1 min read
On November 15, 2022, Dr. Funda Meric-Bernstam and colleagues from the University of Texas MD Anderson Cancer Center published results in The Lancet Oncology from the Phase 1 clinical trial (NCT02892123) evaluating the efficacy and safety of Zanidatamab in patients with HER2-expressing or overexpressing locally advanced or metastatic solid tumors.
This Phase 1 trial was a multi-center dose-escalation study administering Zanidatamab (5 mg/kg to 30 mg/kg, every 1–3 weeks) to patients with HER2-expressing or overexpressing locally advanced or metastatic solid tumors. Part 1 primary endpoint was maximum tolerated dose (MTD); Part 2 primary endpoint was safety.
Results:
Part 1 enrolled 46 patients. No MTD or dose-limiting toxicities were identified. The recommended Phase 2 dose was determined to be 20 mg/kg every 2 weeks. Part 2 enrolled 86 patients. Most common adverse events included diarrhea (43%, N=37/86) and infusion-related reactions (34%, N=29/86). Grade 3 adverse events occurred in 3% (N=4/132). Of the 83 patients evaluable for efficacy in Part 2, 31 had confirmed objective responses.
Conclusion: Based on the Phase 1 trial results, Dr. Meric-Bernstam and colleagues concluded that Zanidatamab may demonstrate efficacy in HER2-expressing or overexpressing locally advanced or metastatic solid tumors, including biliary tract cancer, colorectal cancer, and other tumor types.
Source: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00621-0/fulltext
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4